A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results

被引：0
|
作者：
Moreno, M. [1 ]
Gantz, I. [2 ]
Erondu, N. [2 ]
Suryawanshi, S. [2 ]
Musser, B. [2 ]
Nayee, J. [2 ]
Johnson-Levonas, A. O. [2 ]
Heymsfield, S. [2 ]
Amatruda, J. [2 ]
机构：
[1] Univ Catolica Chile, Fac Med, Dept Nutr Diabet & Metab, Santiago, Chile
[2] Merck Res Labs, Rahway, NJ USA
来源：
CIRCULATION | 2008年 / 118卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E415 / E415
页数：1
相关论文
共 50 条
  • [1] A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results
    Proietto, J.
    Gantz, I
    Carr, R. D.
    Erondu, N.
    Moreno, M.
    Suryawanshi, S.
    Musser, B.
    Nayee, J.
    Johnson-Levonas, A. O.
    Heymsfield, S.
    Amatruda, J.
    INTERNATIONAL JOURNAL OF OBESITY, 2008, 32 : S22 - S22
  • [2] A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results
    Gantz, Ira
    Erondu, Ngozi
    Suryawanshi, Shailaja
    Musser, Bret
    Nayee, Jagriti
    Johnson-Levonas, Amy O.
    Heymsfield, Steven
    Amatruda, John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A326 - A327
  • [3] A TWO-YEAR STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF TARANABANT IN OBESE PATIENTS: 52 WEEK RESULTS
    Carr, R. D.
    Gantz, I.
    Erondu, N.
    Moreno, M.
    Suryawanshi, S.
    Musser, B.
    Nayee, J.
    Johnson-Levonas, A. O.
    Heymsfield, S.
    Amatruda, J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 12 - 12
  • [4] A Two-Year Study to Assess the Efficacy, Safety and Tolerability of Taranabant, a Highly Selective CB1-R Inverse Agonist, in Obese Patients: 104-Week Results
    Aronne, Louis J.
    Tonstad, Serena
    Gantz, Ira
    Erondu, Ngozi
    Sieberts, Solveig
    Molony, Cliona
    Suryawanshi, Shailaja
    Nayee, Jagriti
    Levonas, Amy
    Heymsfield, Steven
    Kaufman, Keith
    Amatruda, John
    OBESITY, 2008, 16 : S89 - S89
  • [5] A One-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant, a Highly Selective CB1-R Inverse Agonist, in Overweight and Obese Patients with Type 2 Diabetes (T2DM): 52-Week Results
    Carr, Richard D.
    Heymsfield, Steven
    Suryawanshi, Shailaja
    Chou, Margaret Zeng
    Harp, Joyce B.
    Kaufman, Keith D.
    Amatruda, John M.
    Kipnes, Mark
    Hollander, Priscilla
    Fujioka, Ken
    Gantz, Ira
    Seck, Thomas
    Erondu, Ngozi
    Shentu, Yue
    Lu, Kaifeng
    OBESITY, 2009, 17 : S134 - S134
  • [6] A One-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant, a Highly Selective CB1-R Inverse Agonist, in Overweight and Obese Patients with Type 2 Diabetes: 36-Week Results
    Kipnes, Mark
    Hollander, Priscilla
    Gantz, Ira
    Seck, Thomas
    Eronda, Ngozi
    Shenta, Yue
    Lu, Kaifeng
    Suryawanshi, Shailaja
    Chou, Margaret
    Davies, Michael
    Heymsfield, Steven
    Kaufman, Keith
    OBESITY, 2008, 16 : S293 - S293
  • [7] A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia
    Canetti, M
    Moreira, M
    Mas, R
    Illnait, J
    Fernandez, L
    Fernandez, J
    Diaz, E
    Castano, G
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 1995, 15 (04) : 159 - 165
  • [8] Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis
    Harris, ST
    Watts, NB
    Li, Z
    Chines, AA
    Hanley, DA
    Brown, JP
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (05) : 757 - 764
  • [9] A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes
    Kipnes, M. S.
    Hollander, P.
    Fujioka, K.
    Gantz, I.
    Seck, T.
    Erondu, N.
    Shentu, Y.
    Lu, K.
    Suryawanshi, S.
    Chou, M.
    Johnson-Levonas, A. O.
    Heymsfield, S. B.
    Shapiro, D.
    Kaufman, K. D.
    Amatruda, J. M.
    DIABETES OBESITY & METABOLISM, 2010, 12 (06): : 517 - 531
  • [10] Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study
    Mallucci, Giulia
    Annovazzi, P.
    Miante, S.
    Torri-Clerici, V.
    Matta, M.
    La Gioia, S.
    Cavarretta, R.
    Mantero, V.
    Costantini, G.
    D'Ambrosio, V.
    Zaffaroni, M.
    Ghezzi, A.
    Perini, P.
    Rossi, S.
    Bertolotto, A.
    Rottoli, M. R.
    Rovaris, M.
    Balgera, R.
    Cavalla, P.
    Montomoli, C.
    Bergamaschi, R.
    JOURNAL OF NEUROLOGY, 2018, 265 (08) : 1850 - 1859
12345